| Literature DB >> 28702078 |
Yulin Zhang1, Yeer Liang1, Chengwei He1.
Abstract
In traditional Chinese medicine (TCM) theory, pathogenic heat and toxins, which are akin to the inflammatory factors, are the causes of cancer and could promote its virulent development. Therefore, heat-clearing and detoxicating (HCD) herbs are essential components of TCM formulas for cancer treatment. An increasing interest has been focused on the study of HCD herbs and accumulated evidences have shown that HCD herbs or HCD herbs-based formulas exhibited remarkable anticancer effects when used alone or combined with other therapeutic approaches. Some of the HCD herb-derived products have been tested in clinical trials. Studies revealed that extracts or pure compounds of the HCD herbs showed a broad anticancer spectrum against both solid and hematologic malignancies without significant toxic effects. Notably, some HCD herbs or formulas could strongly enhance the anticancer activities of chemo- or radio-therapy and alleviate their side effects. The anticancer activities of HCD herb exacts or the pure compounds were reported to be through multiple cellular or molecular mechanisms, such as induction of cancer cell apoptosis, differentiation and cell cycle arrest, inhibition of cancer cell growth, invasion and metastasis, and inhibition of tumor angiogenesis. In this review, we provide comprehensive analysis and summary of research progress and future prospects in this field to facilitate the further study and application of HCD herbs.Entities:
Keywords: Anticancer, cellular and molecular mechanisms; Heat-clearing and detoxicating herbs; Traditional Chinese medicine
Year: 2017 PMID: 28702078 PMCID: PMC5506596 DOI: 10.1186/s13020-017-0140-2
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fig. 1Chemical structures of major anticancer compounds in the representative HCD herbs
The major active components, anticancer effects and mechanisms of HCD herbs
| HCD herbs | Major anticancer compounds | Cancer types (cell lines) | Cellular effects | Molecular mechanisms | References |
|---|---|---|---|---|---|
|
| Baicalein, wogonin | Esophageal squamous cell carcinoma (EC-109), glioma (U87MG, U251MG, C6, U251), colon cancer (HCT116), bladder cancer (TSGH8301, BFTC905, RT4, T24, HT1376), breast cancer (T47D, MCF-7, SK-BR-3, MDA-MB-231, SKBR3), leukemia (CEM), pancreatic carcinoma (Colo-357), hepatocellular carcinoma (HepG2, SK-HEP-1), Hodgkin’s lymphoma (L1236), melanoma (SK-MEL-37), nasopharyngeal carcinoma (NPC-TW076, NPC-TW039) | Inhibiting proliferation, invasion, migration and angiogenesis, inducing apoptosis and differentiation | ↓MMP2, ↓MMP9, ↑TIMP1, ↑TIMP2, ↓p38, ↑PI3K/AKT, ↓NF-κB, ↑PPAP γ, ↓CDC2-survivin, ↓Wnt, ↓CDK9, ↓HIF-1α, ↓VEGF, ↑GSK3β/β-catenin, ↓ΔNp63, ↑cleaved PARP, ↑caspase-3, ↑caspase-7, ↑p21 | [ |
|
| Berberine | Breast cancer (MCF7, MDA-MB-468), gastric cancer (MKN-74), colon cancer (HCT116, SW480, SW620, DLD-1, KM12, KM12SM, KM12L4A,), esophageal cancer (YES-1, YES-2, YES-3, YES-4, YES-5, YES-6), nasopharyngeal carcinoma (5-8F, C666-1), kidney cancer (G401), bladder cancer (T24), hepatocellular carcinoma (HepG2) | Inhibiting proliferation, invasion, migration and angiogenesis, inducing apoptosis, cell cycle arrest at G0/G1 phase and mitochondrial membrane damage, increasing ROS | ↑IFN-β, ↑TNF-α, ↓Cyclin B1, ↓CDC2, ↓Ezrin, ↑p27, ↑p21, ↑Cyclin E, ↑AMPK, ↑WTX, ↓GSK3β/β-catenin, ↓JNK/p38, ↓Wnt, ↓STAT3, ↑caspase-8, ↑caspase-3, ↓Bid, ↑Bax/Bcl-2, ↑Fas, ↑cleaved PARP, ↓NAT, ↓COX-2, ↑TRAIL, ↑VEGF | [ |
|
| Artemisinin | Leukemia (HL-60, NB4), ovarian cancer (HO-8910), prostate cancer (LNCaP), breast cancer (MCF-7), nasopharyngeal carcinoma (CNE-1, CNE-2), hepatocellular carcinoma (HepG2, SMMC-7721), melanoma (A375P, A375M), myeloma (RPMI 8226), colon cancer (HCT16), cervical cancer (HeLa, Caski) | Inhibiting proliferation, invasion, migration and angiogenesis, Inducing apoptosis, cell cycle arrest at G1 phase and mitochondrial dysfunction, increasing ROS | ↑MAPKs, ↓p38MAPK, ↓VEGF, ↓KDR, ↓CDK2, ↓CDK4, ↓cyclin E, ↓cyclin D1, ↓E2F1, ↓BMI-1, ↑RKIP, ↓Bcl-2, ↑Bax, ↑caspase-3, ↓IGF-IR, ↓MMP2, ↓TIMP2, ↓αVβ3, ↓NF-κB | [ |
|
| Ursolic acid, methylanthraquinone | Histocytic lymphoma (U937), leukemia (HL-60), colon cancer (HT-29), melanoma (B16-F10), lung cancer (A549), breast cancer (MCF-7), prostate cancer (LNCaP), Tsu-Pr1, MDA-MB-453, DU-145, cervical cancer (C-33A, U14), sarcoma (S180), hepatocellular carcinoma (HepG2, H22, SMMC-7721) | Inhibiting proliferation, migration and angiogenesis, inducing differentiation, apoptosis, cell cycle arrest at G0/G1, S or G2/M phases, DNA fragmentation and mitochondrial dysfunction | ↑interferon-γ, ↑TNF-α, ↑IL-1, ↓NF-κB, ↑Fas, ↑p53, ↑p21/Cip1, ↓p27/kip1, ↑caspase-3, ↑caspase-9, ↑AP-1, ↓Bcl-2, ↑Bax, ↓STAT3, ↓cyclin D, ↓cyclin D1, ↓cyclin D2, ↓cyclin E, ↓CDK4, ↓CDK2, ↓E2F1, ↑Fas-L, ↑TRAIL, ↓MAPK/ERK, ↓JNK, ↑PI3K, ↑p21/WAF1, ↑CDKN1A, ↓cyclin A2, ↓cyclin B1, ↓ODC1, ↓VEGF-α, ↑HSP 70, ↑P16, ↓pim-1, ↓rel, ↓ras, ↓fos, ↓myc, ↑IFN-γ | [ |
|
| Oridonin | Hepatocellular carcinoma (HepG2), gallbladder carcinoma (SGC996, NOZ), breast cancer (MCF-7, MDA-MB-231), cervical cancer (HeLa), histiocytic lymphoma (U937), pancreatic cancer (SW1990) | Inhibiting proliferation, migration and invasion, inducing apoptosis, autophagy, DNA damage and cell cycle arrest at S and G2/M phases, increasing ROS | ↑Hsp70-1, ↑STAP, ↑TCTP, ↑Sti1, ↑PPase, ↓hnRNP-1, ↑HP1 β, ↑GlyRS, ↓NF-κB, ↑Bax/Bcl-2, ↑caspase-3, ↑caspase-9, ↑cleaved PARP, ↓IKKα, ↓IKKβ, ↓mTOR, ↑Fas, ↑PPAR-γ, ↓MMP2/MMP9, ↓Integrin β, ↓FAK, ↓Akt, ↓FOXO, ↓GSK3, ↓ERK, ↓IL-1β, ↑Beclin-1, ↑LC3 II/I, ↑Atg4B, ↓p38 MAPK, ↑p53, ↑p21 | [ |
|
| Apigenin, luteolin | Hepatocellular carcinoma (MHCC97H), colon cancer (HT-29), leukemia (LM-1, LM-2), cervical cancer (HeLa) | Inhibiting proliferation and invasion, inducing apoptosis, differentiation and cell cycle arrest at G1 phase | ↓MMP-2, ↓MMP-9, ↑TIMP-1, ↑TIMP-2, ↑ACTA2, ↑Calponin, ↑p27, ↓Cyclin D1, ↓CDK4, ↑p21, ↑Bax/Bcl-2, ↓STAT3, ↓ERK1/2, ↓p38, ↑Smac, ↑Apaf-1, ↑caspase-9, ↑caspase-3, ↓IGF-1, ↑cytochrome c | [ |
|
| Saikosaponin D | Cervical cancer (HeLa), breast cancer (MCF-7), prostate cancer (PC3), lung cancer (H1299, LLC-1, A549), hepatocellular carcinoma (HepG2, Hep3B), gastric adenocarcinoma (MK-1), cervical cancer (HeLa), melanoma (B16F10), leukemia (P-388), oral epidermoid carcinoma (KB) | Inhibiting proliferation, invasion, metastasis, and angiogenesis, inducing apoptosis, autophagic cell death, cell cycle arrest at G1, or G2/M phases | ↑ERK1/2, ↑caspase-3, ↑caspase-9, ↑caspase-7, ↑cleaved PARP, ↑AMPK, ↑mTOR, ↑p27, ↓p53, p21/WAF1, ↑Fas/APO-1, ↑mFasL, ↑sFasL, ↑Bax, ↓IKB-α, ↓NF-κB, ↓Bcl-XL, ↓SERCA Ca2+ pump, ↑[Ca2+]i, ↓telomerase, ↑tubulin polymerization | [ |
|
| Matrine | Hepatocellular carcinoma (H22, S180, SMMC-7721, HepG2, Hep-7402), breast cancer (MA737, MKN45, SGC-70901, MDA-MB-231), gastric cancer (SGC-7901), melanoma (A375, SK-MEL-2, M21, B16-F10), cervical cancer (HeLa), leukemia (K-562), glioma (C6), lung cancer (A549, NCI-H460), ovarian cancer (SK-OV-3), central nervous system cancer (XF498), pulmonary adenoma (SPC-A-1), esophagus cancer (Eca-109), colon cancer (SW1116, HCT-15), osteosarcoma (UMR-108, MNNG/HOS), pancreatic cancer (PANC-1), leukmia (U937, HL-60), adenoid cystic carcinoma (ACC-M), retinoblastoma (Y79, WERI-RB1, SO-RB50), nasopharynx cancer (TW03) | Inhibiting proliferation, adhesion, invasion, metastasis and angiogenesis, inducing apoptosis, autophagy, differentiation and cell cycle arrest at G0/G1 or G2 phases, modulating immune function | ↑Beclin 1, ↑Bax, ↓Bcl-2, ↑caspase-8, ↑caspase-3, ↑caspase-9, ↑AKT, ↓NF-κB, ↓IκBα, ↓p65, ↓ERK1/2, ↓JNK, ↓p38 MAPK, ↓TNFαl, ↓IKB-α, ↓p65, ↓ERK1/2, ↑E2F1, ↓Rb, ↑Apaf-1, ↓MMP-9, ↓MMP-2, ↓AKT, ↓EGF, ↓VEGF, ↓VEGF2, ↓VEGFR1, ↑Fas, ↑FasL, ↑p21, ↑p27, ↓Cyclin D1, ↓Cyclin E, ↓hTERT | [ |
|
| Pulsatilla saponin A, D, H | Gastric cancer (MKN-45, MKN-28, AGS), colon cancer (HT-29, LoVo), hepatocellular carcinoma (Huh-7, HepG2) | Inducing DNA damage and apoptosis | ↑Caspase-3, ↑cleaved PARP, ↑Bax, ↓c-Met, ↓AKT, ↓mTOR, ↓p70S6K, ↓HIF-1α, ↓VEGF | [ |
|
| Colchicine | Hepatocellular carcinoma (HCC24/KMUH, HCC38/KMUH) | Inhibit proliferation interacting with tubulin | ↑AKAP12, ↑TGF-β2, ↑MX1 | [ |
|
| Tectorigenin | Hepatocellular carcinoma (HepG2), lung cancer (LLC), sarcoma (S180), prostate cancer (LNCaP) | Inhibiting the proliferation and angiogenesis, inducing apoptosis, differentiation and mitochondrial dysfunction, increasing ROS | ↑Caspase-3, ↑caspase-9, ↓PDEF, ↓PSA, ↓IGF-1, ↑TIMP-3, ↑cytochrome c, ↑[Ca2+]i | [ |
Fig. 2Schematic diagram showing the anticancer activities and mechanisms of compounds in HCD herbs
Anticancer effects and mechanisms of HCD herb-containing formulas
| HCD formulas | Components | Cancer types (cell lines) | Cellular effects | Molecular mechanisms | References |
|---|---|---|---|---|---|
| Yanshu Injection |
| Hepatocellular carcinoma (HepG2), breast cancer (MDA-MB-231), bladder cancer (T24) | Inhibiting proliferation, adhesion, invasion, migration and metastasis inducing apoptosis and autophagy, modulating immune response | ↓TGF-β1, ↓TGFBR1 | [ |
| Huanglian Jiedu Tang |
| Hepatocellular carcinoma (HepG2, PLC/PRF/5), myeloma (U266, NOP-2, AMO1, ILKM2) | Inhibiting proliferation, inducing apoptosis and cycle arrest | ↑p-Cdc2, ↑p-Cdc25C, ↓Cdc2, ↓Cdc25C, ↓Cyclin A, ↓Cyclin B1, ↑Bak, ↓Bcl-2, ↓Bcl-XL, ↑IKB-α, ↓NF-κB, ↓IL-6, ↓XIAP, ↑caspase-3, ↑caspase-9 | [ |
| Jiedu Xiaozheng Yin |
| Hepatocellular carcinoma (HepG2, PLC/PRF/5, Huh7) | Inhibiting proliferation, inducing apoptosis, cycle arrest at G0/G1 phase and loss of plasma membrane asymmetry, decreasing mitochondrial membrane potential | ↑Cyclin D, ↑Cyclin E, ↓C-myc, ↓Cyclin D1, ↓PCNA, ↓Bmi1, ↑p16, ↑caspase-3, ↑caspase-9, ↑Bax/Bcl-2 | [ |
| PHY906 |
| Hepatocellular carcinoma (HepG2) | Inducing apoptosis | ↑FasL, ↑FasR, ↑hMCP1, ↑AMPKα-T172-P, ↑ULK1-S555-P, ↑ERK1/2-P | [ |
| Feiji Recipe |
| Lung cancer (LLC) | Inhibiting proliferation, intervening immune escape | ↓CD4+CD2+Tr, ↓VEGF, ↓Scd44V6, ↓TGR-β1, ↓IL-10 | [ |
| YiQi ChuTan Recipe |
| Lung cancer (A549, LLC) | Inhibiting proliferation and metastasis, reversing EMT | ↓GRP78, ↓smad2/3, ↓SRC/MAPK, ↑Caspase-4, ↑DNA-PK, ↓Hspd1, ↓PH, ↓PDI, ↓EG433182, ↓HSPA 5 precursor, ↓HSPA 9, ↓PP1, ↓PRDX-1, ↓PRDX-6 | [ |
| Jianpi Yangzheng Xiaozheng Recipe |
| Gastric cancer (MGC-803) | Inducing apoptosis and autophagy | ↑Bax, ↓Bcl-2, ↓cyclin D1, ↓cyclin D2, ↓cyclin D3, ↑Fas, ↓procaspase-3, ↓procaspase-8, ↓procaspase-9, ↑cleaved-PARP, ↑Beclin-1, ↑LC3 II | [ |
| Fuzheng Qingjie Recipe |
| Hepatocellular carcinoma (HepG2) | Inducing apoptosis | ↑caspase-9, ↑caspase-3, ↑P38 MAPK, ↑Bax, ↓Bcl-2 | [ |
| Baihe Recipe |
| Gastric cancer (BGC-823) | Inhibiting proliferation and metastasis | ↓VEGF, ↓p53 | [ |
| Weikangfu Granule |
| Sarcoma (S180) | Inducing apoptosis and cell cycle arrest at G0/G1 phase, modulating immune response | ↑p53, ↑Bax, ↓Bcl-2 | [ |